Bandala-Sanchez, E.Bediaga, N.G.Naselli, G.Neale, A.M.Harrison, L.C.2022-05-122022-05-122020Human Immunology, 2020; 81(2-3):101-1040198-88591879-1166https://hdl.handle.net/2440/135046Most sialic acid–binding immunoglobulin-like lectins (Siglecs) suppress immune cell function but are expressed at low levels on human T cells. We found that soluble CD52 inhibited T cell signalling by ligating Siglec-10, but the presence of Siglec-10 on human T cells has been questioned. To address this concern, we examined the expression of Siglec-10 at the RNA and protein level in human CD4+ T cells. Analysis by RNAseq, qPCR and flow cytometry demonstrated that, in contrast to other Siglecs, after activation of CD4+ T cells Siglec-10 was selectively upregulated in a subset of cells also high for CD52 expression. This observation is consistent with a homeostatic role for Siglec-10 in human CD4+ T cells.en© 2020 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.CD4+ T cell; Activation; Siglec-10; Protein; RNA; CD52CD4-Positive T-LymphocytesHumansLectinsReceptors, Cell SurfaceLymphocyte ActivationUp-RegulationCD52 AntigenJournal article10.1016/j.humimm.2020.01.0092022-05-12610285